Copyright
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. May 7, 2024; 30(17): 2321-2331
Published online May 7, 2024. doi: 10.3748/wjg.v30.i17.2321
Published online May 7, 2024. doi: 10.3748/wjg.v30.i17.2321
Efficacy and safety of targeted therapy plus immunotherapy combined with hepatic artery infusion chemotherapy (FOLFOX) for unresectable hepatocarcinoma
Zhi-Peng Lin, Xiao-Long Hu, Du Chen, Da-Bei Huang, Xu-Gong Zou, Hai Zhong, Sheng-Xiang Xu, Yuan Chen, Xiao-Qun Li, Jian Zhang, Department of Interventional Medicine, Zhongshan People’s Hospital, Zhongshan 528400, Guangdong Province, China
Author contributions: Lin ZP and Zhang J conceived and designed the study; Lin ZP, Hu XL, Chen D, Huang DB, Zou XG, Zhong H, Xu SX, and Chen Y contributed to data collection and analysis; Lin ZP drafted the manuscript; Lin ZP, Li XQ, and Zhang J supervised data analysis and interpretation, revised the manuscript, and gave final approval for the version to be published; and all authors read and approved the final manuscript.
Institutional review board statement: This study was reviewed and approved by the Ethics Committee of Zhongshan People’s Hospital (Approval No. 2022-029).
Informed consent statement: Study participants were not required to give informed consent because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.
Data sharing statement: All data and materials are available from the corresponding author.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jian Zhang, Doctor, Associate Chief Physician, Department of Interventional Medicine, Zhongshan People’s Hospital, No. 2 Sun Wen East Road, Zhongshan 528400, Guangdong Province, China. wy18988583838@163.com
Received: February 19, 2024
Revised: March 25, 2024
Accepted: April 9, 2024
Published online: May 7, 2024
Processing time: 76 Days and 2.2 Hours
Revised: March 25, 2024
Accepted: April 9, 2024
Published online: May 7, 2024
Processing time: 76 Days and 2.2 Hours
Core Tip
Core Tip: The therapeutic strategy of combining multiple modes of drug delivery for the treatment of hepatocellular carcinoma (HCC) has been shown to be more efficacious than single treatment modality, but the underlying mechanism of action has not been clarified. In this study, we observed the clinical efficacy of targeted therapy plus immunotherapy combined with FOLFOX hepatic artery infusion chemotherapy in the treatment of unresectable HCC, which provides a clinical basis for the clinical application of the combination of therapy in HCC.